Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 18/20 | 0.70 |
| ▸ | NPY2R | P49146 | 1/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6480135 | 1.00 | BDKRB1 (0.70) | BDKRB1NPY2RHCRTR1HCRTR2 | |
| Hydrochloric Acid SCHEMBL6187618 | 0.86 | BDKRB1 (0.73) | BDKRB1 | |
| SCHEMBL6181950 | 0.83 | BDKRB1 (1.00) | BDKRB1 | |
| Hydrochloric Acid SCHEMBL6184751 | 0.82 | BDKRB1 (0.55) | BDKRB1HCRTR1HCRTR2 | |
| SCHEMBL6185032 | 0.81 | BDKRB1 (0.80) | BDKRB1 | |
| SCHEMBL3534819 | 0.75 | BDKRB1 (0.55) | BDKRB1 | |
| SCHEMBL20437900 | 0.70 | ACHE (0.49) | BDKRB1NPY2R | |
| SCHEMBL1586134 | 0.70 | HCRTR1 (0.55) | HCRTR1HCRTR2 | |
| SCHEMBL1586661 | 0.68 | HCRTR1 (0.54) | HCRTR1HCRTR2 | |
| SCHEMBL17071971 | 0.68 | HCRTR1 (0.54) | BDKRB1HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501787-B1 | N-BIPHENYLMETHYL AMINOCYCLOALKANECARBOXAMIDE DERIVATIVES WITH A SUBSTIITUENT ON THE METHYL USEFUL AS BRADYKININ ANTAGONISTS | MERCK & CO INC (US) | 2005-11-09 | — | — | EP | disclosed |
| US-6919343-B2 | N-biphenyl(substituted methyl) aminocycloalkane-carboxamide derivatives | MERCK & CO., INC. (US) | 2005-07-19 | — | — | US | disclosed |
| US-20050084463-A1 | N-biphenylmethyl aminocycloalkanecarboxamide derivatives with a substiituent on the methyl useful as bradykinin antagonists | WOOD MICHAEL R (US) | 2005-04-21 | — | — | US | disclosed |
| US-20030220375-A1 | N-biphenyl(substituted methyl) aminocycloalkane-carboxamide derivatives | MERCK SHARP & DOHME LLC | 2003-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220375-A1 | N-biphenyl(substituted methyl) aminocycloalkane-carboxamide derivatives | BDKRB1, BDKRB2, CNR2 | BDKRB1 1/4885NPY2R 388/4885HCRTR1 420/4885 |
| US-20050084463-A1 | N-biphenylmethyl aminocycloalkanecarboxamide derivatives with a substiituent on the methyl useful as bradykinin antagonists | BDKRB1, BDKRB2, CNR2 | BDKRB1 1/4885NPY2R 438/4885HCRTR1 569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.